Once-weekly insulin icodec non-inferior to daily insulin degludec in patients with type 1 diabetes
1. Mean HbA1c reduction at 26 weeks was comparable in the weekly icodec and daily degludec groups. 2. The risk of hypoglycemia was significantly higher among patients taking weekly insulin icodec compared to those taking daily insulin degludec. Evidence Rating Level: 1 (Excellent) Study Rundown: First-line therapy for type 1 diabetes includes a combination of
Source: 2minutemedicine.com